{"id":"W2623725180","doi":"10.1016/s1470-2045(17)30339-x","title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":580,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Ignyta; Shionogi; AstraZeneca; Associazione Italiana per la Ricerca sul Cancro; Astellas Pharma; Eli Lilly and Company","keywords":"Ceritinib; Crizotinib; Medicine; Anaplastic lymphoma kinase; Lung cancer; ALK inhibitor; Internal medicine; Chemotherapy; Oncology; Docetaxel; Pemetrexed; Gastroenterology; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001640221,0.001872703,0.004238739,0.0004347755,0.0003839147,0.0011729,0.0008900173,0.00198939,0.004940008],"category_scores_gemma":[0.001681598,0.0006425027,0.00272164,0.0004682957,0.001312011,0.00150631,0.0004076943,0.003781591,0.0009418449],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001250743,"about_ca_system_score_gemma":0.001048613,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001600024,"about_ca_topic_score_gemma":0.004244637,"domain_scores_codex":[0.9993143,0.0003324719,0.00003958903,0.0001361531,0.00004147819,0.0001360732],"domain_scores_gemma":[0.9991925,0.0002300413,0.0002015714,0.00005166625,0.00003853104,0.0002857256],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9805162,0.002126752,0.0005326234,0.0006082037,0.001110608,0.0000422039,0.0000427969,0.0005551003,0.001462783,0.00009789556,0.000703813,0.01220094],"study_design_scores_gemma":[0.9334598,0.06254014,0.001772992,0.00003481716,0.0005739082,0.0000511763,0.00002686429,0.0005379058,0.0002601848,0.0001480733,0.0005772979,0.00001704742],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.98353,0.009738078,0.0004327325,0.0009686682,0.000851319,0.001471207,0.0006946258,0.0001700895,0.002143346],"genre_scores_gemma":[0.9909536,0.003099607,0.0005757684,0.0008770536,0.000386421,0.000945992,0.0008338797,0.00002198255,0.002305752],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004940008,"threshold_uncertainty_score":0.01652598,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04534884463340635,"score_gpt":0.4133336191056075,"score_spread":0.3679847744722012,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}